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BACKGROUND: Combination chemotherapy is standard treatment for metastatic colorectal cancer (MCRC). The aim of this study was
to determine the efficacy and safety of capecitabineþirinotecan (2-weekly schedule), as first-line therapy of MCRC.
METHODS: Patients received irinotecan 175mgm
 2 on day 1 and oral capecitabine 1000mgm
 2 twice daily on days 2–8 every
2 weeks. For patients aged X65 years, the starting doses of irinotecan and capecitabine were reduced to 140 and 750mgm
 2,
respectively.
RESULTS: A total of 53 patients were enrolled: 29 (55%) were X65 years old. In an intention-to-treat analysis, complete response was
achieved in three patients for an overall response rate (ORR) of 32%. The disease control rate (ORR þ stable disease) was 66% and
the median duration of response was 7.3 months. Median time to progression and overall survival were 9.0 and 19.2 months,
respectively. Grade 4 neutropenia was reported in one patient: no other grade 4 toxicities were recorded. Grade 3 diarrhoea
occurred in 8 (15%) patients and grade 1–2 hand–foot syndrome in 7 (13%) patients.
CONCLUSION: Capecitabine and irinotecan, given every 2 weeks, as first-line treatment of MCRC is an active regimen with a
manageable toxicity profile, even in older patients.
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The addition of irinotecan to infusional (FOLFIRI: every 2 weeks)
or bolus (IFL: weekly) 5-fluorouracil/leucovorin (5-FU/LV) has
been shown to significantly improve progression-free survival,
overall survival (OS), and response rate compared with the
equivalent 5-FU/LV regimens alone in the first-line treatment of
metastatic colorectal cancer (MCRC) (Douillard et al, 2000; Saltz
et al, 2000). However, FOLFIRI appears to be better tolerated than
IFL and is associated with a lower frequency of toxicities such as
diarrhoea, myelosuppression, and sepsis (Benson and Goldberg,
2003; Alimonti et al, 2004; Hwang, 2004).
Several studies show that patients have a strong preference for
oral, rather than intravenous, chemotherapy (Liu et al, 1997;
Borner et al, 2002; Twelves et al, 2006): the main reasons for this
include convenience, problems with intravenous lines (pain,
thrombosis or infection; Mueller et al, 1992), and the opportunity
to control the environment in which chemotherapy is received.
Capecitabine, an inactive oral prodrug, which is preferentially
converted to 5-FU in tumour tissue (Meropol, 1998), has emerged
as an attractive oral alternative to intravenous 5-FU. Twice-daily
oral administration of capecitabine results in continuous exposure
to 5-FU, thus avoiding the need for central venous access.
Capecitabine has shown, in large-scale randomised studies in
patients with MCRC, a significantly superior response rate and at
least equivalent OS compared with bolus 5-FU/LV (Hoff et al, 2001;
Van Cutsem et al, 2001). Moreover, capecitabine showed a
superior safety profile with significantly less cases of neutropenia,
alopecia, diarrhoea, and stomatitis, but more cases of hand–foot
syndrome (Cassidy et al, 2002). Following these results, several
investigators tested the combination of irinotecan with capecita-
bine in an attempt to improve on the available 5-FU/LV-based
regimens. Encouraging efficacy results from phase II studies were
reported with combination regimens of capecitabine and irinote-
can given weekly, on days 1 and 8 (CAPIRI) or 3-weekly (XELIRI)
as first-line treatment for MCRC (Bajetta et al, 2004; Park et al,
2004; Borner et al, 2005; Cartwright et al, 2005; Kim et al, 2005;
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sRea et al, 2005; Patt et al, 2007). However, dose reductions of both
drugs were necessary in most studies to improve the safety profile
of these regimens. The 3-weekly XELIRI regimen was selected for
further testing in phase III studies. Although the large CAIRO
study (Koopman et al, 2007) showed that, with careful dose
management, the XELIRI regimen was effective and had an
acceptable tolerability profile, XELIRI was associated with
unacceptable toxicity in two other phase III trials (Fuchs et al,
2007; Kohne et al, 2008). These data suggest that the optimal doses
and schedule for the capecitabine–irinotecan combination have
yet to be identified.
The objective of this phase II study was to evaluate the feasibility
of a new 2-weekly schedule of capecitabine and irinotecan (similar
to the FOLFIRI scheme) in an attempt to improve the tolerability
of this combination as first-line therapy in patients with MCRC.
MATERIALS AND METHODS
Local ethics committee approval was obtained before enrolment of
any patient into this multicentre, national, open-label, phase II
trial. It was conducted in accordance with the Declaration of
Helsinki Principles and its subsequent amendments, as well as
Good Clinical Practice Guidelines. Signed informed consent was
obtained from all patients before study entry.
The primary study objective was to determine the overall
response rate (ORR) to the 2-weekly capecitabine–irinotecan
regimen. Secondary objectives included duration of response, time
to progression (TTP), OS, and tolerability.
Eligibility criteria
Patients with histologically confirmed locally advanced colorectal
cancer or MCRC, which was measurable according to the RECIST
criteria (Therasse et al, 2000), were eligible. Patients were either
chemotherapy-naive or were to have undergone adjuvant chemo-
therapy X6 months before study entry. Other eligibility criteria
included: age 18–75 years; Eastern Cooperative Oncology Group
(ECOG) performance status p2; life expectancy of more than
3 months; adequate haematological, liver, and renal function (i.e.,
haemoglobin X10gdl
 1, absolute neutrophil count of X1.5 
10
9l
 1, and platelets X100 10
9l
 1; total bilirubin p1.25  the
upper limit of normal (ULN), serum transaminase and alkaline
phosphatase levels of p2.5 ULN (total bilirubin p1.5 ULN,
serum transaminase and alkaline phosphatase levels p5 ULN,
in case of liver metastases); creatinine p1.5 ULN); absence of
any primary tumour other than non-melanoma skin cancer or
in situ cervical carcinoma. Patients with central nervous system
metastasis, unresolved bowel obstruction or subobstruction,
inflammatory enteropathy, malabsorption syndrome, any uncon-
trolled chronic disease, or organ allografts were excluded.
Treatment schedule
On the basis of our previous phase I study (Garcia-Alfonso
et al, 2003), patients received irinotecan 175mgm
 2 as a 30-min
intravenous infusion on day 1, followed by oral capecitabine
1000mgm
 2 twice daily on days 2–8, every 2 weeks. Taking into
consideration the irinotecan package insert suggestions (i.e.,
caution in patients X65 years and a lower dose in patients
X70 years), the starting doses of both irinotecan and capecitabine
were reduced to 140 and 750mgm
 2 twice daily, respectively, in
patients X65 years of age. The study treatment was continued
until disease progression, severe toxicity, treatment refusal
(unrelated to toxicity), investigator decision, or death.
Both drugs were administered according to the guidelines
used for irinotecan monotherapy, including recommendations for
the use of concurrent antiemetics, atropine, and loperamide.
Appropriate dose interruptions/reductions for capecitabine and/or
irinotecan were implemented in the event of specific toxicities,
depending on their nature and intensity.
Patients were assessed for toxicity before each infusion using the
National Cancer Institute-Common Toxicity Criteria (NCI-CTC,
version 2.0) of April 1999.
Evaluations during the study
Physical examination and laboratory studies, including complete
blood counts, serum liver function tests, calcium, ions, and
creatinine levels, were performed within 7 days of enrolment.
Electrocardiography was carried out and carcinoembryonic
antigen levels were determined within 21 days before starting of
the treatment. A chest radiograph or computed tomography (CT)
scan, and abdominal CT scan were completed within 4 weeks of
enrolment. During treatment, safety assessments, biochemical
analysis, and blood counts were performed before each cycle
(every 2 weeks).
Evaluation of disease status, according to the RECIST criteria
(Therasse et al, 2000), was carried out every three cycles (6 weeks)
during treatment, and every 8 weeks subsequently until disease
progression, death, or loss to follow-up.
The duration of response was measured from the first
documentation of response to disease progression (PD). TTP was
calculated as the time from inclusion in the study until the first
report of PD. Patients with no evidence of PD at the time of their
last visit were censored at that time. OS was measured from the
time of inclusion to date of death.
Statistical considerations
Sample size was calculated using the optimal method described by
Simon (1989). We assumed a minimum efficacy (p0) of 20% and
an optimal 40% response rate with the study combination (p1)
(similar to the 35–39% obtained with the combination of
irinotecan and 5-FU/LV in two pivotal trials; Douillard et al,
2000; Saltz et al, 2000), with a- and b-error probabilities of 0.05
and 0.1, respectively. With these considerations, if X16 of a total
of 54 patients responded to treatment, further phase III or other
trials would be warranted.
All efficacy and safety analyses were carried out on the
intention-to-treat (ITT) population, which included all recruited
patients. The probabilities of time-to-event parameters were
estimated using the Kaplan–Meier method with 95% confidence
intervals (95% CIs).
RESULTS
Between June 2002 and January 2005, a total of 53 patients from
three Spanish centres were enrolled into the study. The baseline
characteristics of the patients are summarised in Table 1. Of these,
47 (89%) patients had an ECOG performance status of o2a t
baseline, 29 (55%) were at least 65 years old, and 57% had at least
two organs involved (median 2 and maximum 8), with the liver
being the most common site of metastatic disease.
Treatment compliance
A total of 489 cycles were administered with a median of 11
(range 2–12) cycles per patient. Irinotecan doses were delayed in
56 cycles (12%), and dose reductions were required in 33 cycles
(7%). Globally, 3423 doses of capecitabine were administered:
of those, 106 administrations (3.1%) were delayed, and dose
reductions were required in 171 cases (5%). No significant
differences in drug administrations were observed between
patients aged 465 and p65 years.
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All patients were evaluable for toxicity. The main haematological
and non-haematological toxicities by patient are summarised in
Table 2. Grade 4 neutropenia was reported in one patient; no other
grade 4 toxicities were recorded. The most frequent non-
haematological toxicities were gastrointestinal events (i.e. nausea,
vomiting, and diarrhoea), as well as alopecia and asthenia; in most
cases, these toxicities did not reach grade 42. In particular, grade
3 diarrhoea was uncommon (eight patients, 11 cycles), and grade
1–2 hand–foot syndrome was observed in seven patients (no
grade 42 hand–foot syndrome was reported).
No significant differences related to toxicity were observed in
patients aged X65 years and those o65 years, although there was
a tendency for a later recovery in older patients (data not shown).
There were no treatment-related deaths during the study or
within 28 days after the last study dose.
Efficacy assessment
In an ITT analysis, in which all 53 patients were considered, 3 (6%)
patients attained a complete response and 14 patients a partial
response, for an ORR of 32% (95% CI: 20–46%). In addition, 18
(34%) patients had stable disease, providing a disease control rate
(ORR þ stable disease) of 66% (95% CI: 52–79%). The median
duration of response was 7.3 (95% CI: 6.2–8.8) months.
The median TTP and OS were 9.0 (95% CI: 5.7–10.4) and 19.2
(95% CI: 14.1–23.3) months, respectively.
DISCUSSION
Combination chemotherapy is standard treatment for MCRC,
often combined with a biological agent. Until recently oxaliplatin
regimens have probably been the most used as first line treatment
of MCRC, but as oxaliplatin adjuvant therapy is now usually
selected, irinotecan combinations are more likely to be used at first
progression. Combining irinotecan with capecitabine will make a
regimen that is better tolerated and preferred by patients.
This phase II study shows that a novel 2-weekly schedule of
capecitabine plus irinotecan as first-line treatment for MCRC is
feasible, with notable efficacy and safety, even in older patients. To
date, we are not aware of the publication of any other phase II
prospective study of capecitabine plus irinotecan using this
schedule. The choice of this regimen was based on our previous
phase I study (Garcia-Alfonso et al, 2003), which aimed to simulate
the FOLFIRI scheme, thereby replacing 5-FU/LV with oral
capecitabine.
Previous phase II trial results suggested that the 3-weekly
XELIRI regimen was less toxic than those involving irinotecan
given on days 1 and 8 (CAPIRI) or on a weekly basis (Bajetta et al,
2004; Borner et al, 2005), but the initial doses used with 3-weekly
XELIRI in those trials had to be reduced in a considerable number
of patients. Moreover, XELIRI showed better efficacy than the
weekly regimen (Borner et al, 2005), probably because of the
higher dose intensity of irinotecan in the XELIRI arm. Thus, the
3-weekly XELIRI regimen was taken forward for phase III testing.
Although XELIRI was found to be effective with a manageable
toxicity profile in the large CAIRO trial (Koopman et al, 2007),
unacceptable rates of toxicity were reported in both the EORTC
40015 (Kohne et al, 2008) and BICC-C (Fuchs et al, 2007) studies,
both of which compared XELIRI with 5-FU-based irinotecan
combinations with a second randomisation to placebo or
celecoxib. These findings suggested that the optimal capecita-
bine–irinotecan schedule had not yet been identified.
Although a comparison of results from different phase II studies
can be only speculative, the efficacy of our schedule is in line with
that obtained by the other groups who have also published
response data in phase II trials testing capecitabine–irinotecan
combination regimens (Bajetta et al, 2004; Park et al, 2004; Borner
et al, 2005; Cartwright et al, 2005; Kim et al, 2005; Rea et al, 2005;
Patt et al, 2007; Choi et al, 2008) (Table 3). Indeed, our median
TTP and OS are among the highest of those published to date with
this combination. Moreover, the time-to-event results in this study
Table 1 Patient characteristics (n¼53)
Parameter No. of patients %
Sex
Male 39 74
Female 14 26
Age, years
Median 66
Range 42–80
ECOG performance status
01 7 3 2
13 0 5 7
23 6
Non-specified 3 6
Primary site
Colon 30 57
Rectum 22 41
Both 1 2
Metastatic site
Liver 31 61
Lung 13 26
Peritoneum 8 16
Other 15 29
Prior therapy
Radiotherapy 10 19
Surgery 41 77
Adjuvant chemotherapy 22 42
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 2 Maximum toxicity per patient according to the NCI-CTC grade
(n¼53)
All grades Grade 3
n % n %
Haematological events
Anaemia 23 43 — —
Leucopenia 4 8 — —
Neutropenia 12 23 3 6
Thrombopenia 3 6 1 2
Non-haematological events
Fever 8 15 — —
Alopecia 14 26 2 4
Nausea 30 57 4 8
Vomiting 24 45 2 4
Diarrhoea 27 51 8 15
Epigastralgia 8 15 1 2
Asthenia 30 57 7 13
Headache 3 6 — —
Hand–foot syndrome 7 13 — —
Mucositis 11 21 — —
Liver 2 4 — —
Renal 2 4 1 2
Skin 3 6 — —
Anorexia 11 21 1 2
Abbreviation: NCI-CTC¼National Cancer Institute-Common Toxicity Criteria.
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trials of the FOLFIRI regimen (Tournigand et al, 2004; Van Cutsem
et al, 2007): median TTP (9.0 vs progression-free survival of 8.0
and 8.5 months) and median OS (19.2 vs 21.5 months).
It is noteworthy that the regimen tested in this study shows good
tolerability (dose reductions were required in only 7% of cycles),
with predominantly mild or moderate adverse events only.
Importantly, there were no treatment-related deaths during our
study. No grade 4 non-haematological toxicities were reported and
only one case (3%) of non-complicated grade 4 neutropenia was
documented. As expected with this combination, diarrhoea was the
main adverse event, but with a low rate of grade 3 events (15% of
patients) and no grade 4 events. Hand–foot syndrome, a well-
documented capecitabine-associated event, was only reported in
seven patients and all cases were grade 1 or 2. In Table 3, which
summarises the main grade 3–4 toxicities per patient reported in
previous phase II studies testing the combination of capecitabine
and irinotecan, the improved tolerability of the 2-weekly regimen
is notable: grade 3–4 neutropenia and diarrhoea ranged between
5–28 and 8–34% in other phase II studies, respectively, compared
with respective rates of 6 and 15% in this study. Unlike the current
study, grade 3–4 hand–foot syndrome was reported in most of
those studies (Cartwright et al, 2005; Patt et al, 2007; Choi et al,
2008). Our regimen also appears to be associated with a lower rate
of grade 3–4 neutropenia (6 vs 24–23%) and a similar rate of
grade 3–4 diarrhoea (15 vs 14–11%) compared with FOLFIRI
(Tournigand et al, 2004; Van Cutsem et al, 2007).
Implementation of up-front dose reductions in older patients
also appears to have contributed to a better tolerability profile than
has been previously reported for other capecitabine–irinotecan
regimens. This approach has also been used successfully with the
XELIRI regimen in patients with other known risk factors, for
example, renal impairment, previous pelvic irradiation, and older
age (Patt et al, 2007; Van Cutsem et al, 2007).
In conclusion, 2-weekly administration of irinotecan in combi-
nation with capecitabine is effective and safe as first-line
chemotherapy for advanced colorectal cancer or MCRC and may
be suitable for use with targeted agents, such as cetuximab or
bevacizumab. Therefore, phase III studies of this regimen are
warranted.
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